Clinical Trial Update: A Pilot Study to Determine the Safety of Campath-1H (Anti-CD52 Antibody) Therapy in Newly Diagnosed Subjects With Type 1 Diabetes Mellitus [Phase 1]

View source ↗

Summary

Phase 1 pilot trial assessing the safety of Campath-1H (alemtuzumab) in individuals with newly diagnosed Type 1 diabetes mellitus; the study has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Campath-1H (alemtuzumab)

Snippet

Sponsor: University of Wisconsin, Madison | Conditions: New Onset Type 1 Diabetes Mellitus | Phase 1 | Status: WITHDRAWN